Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has issued an announcement.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co recently entered into an agreement with the Bank of China to subscribe to a structured deposit product worth RMB200 million. This transaction, using temporary idle proceeds from the public issuance of A shares, is considered a disclosable transaction under the Listing Rules but is exempt from shareholder approval. The deposit product is principal-guaranteed with a floating return, linked to the central parity price of Gold/USD, and assessed as low-risk by the Bank of China.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
For detailed information about 1349 stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Arm Holdings Explores Possible Takeover of Ampere Computing
- M&A News: Constellation Energy’s $30B Calpine Takeover Takes Shape
- Cowen Pounds the Table on Sana Biotechnology Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
